Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies

By Deenen Maarten  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1557-1565

Springer Publishing Company

Access to resources Recommend Favorite

Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies

By Sayar H.   Shen Z.   Lee S.   Royce M.   Rabinowitz I.   Lee F.   Smith H.   Eberhardt S.   Maestas A.   Lu H.   Verschraegen C.  

Investigational New Drugs, Vol. 27, Iss. 2, 2009-04 ,pp. : 153-158

Springer Publishing Company

Access to resources Recommend Favorite

A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors

By Heath Elisabeth  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1566-1574

Springer Publishing Company

Access to resources Recommend Favorite

A Novel Combination of Cisplatin, Irinotecan, and Capecitabine in Patients with Advanced Cancer

By Jefford Michael   Michael Michael   Rosenthal Mark A.   Davis Ian D.   Green Michael   McClure Bev   Smith Jennifer   Waite Brigid   Zalcberg John  

Investigational New Drugs, Vol. 22, Iss. 2, 2004-04 ,pp. : 185-192

Springer Publishing Company

Access to resources Recommend Favorite

Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer

By Argiris Athanassios   Kut Victoria   Luong Lynn   Avram Michael  

Investigational New Drugs, Vol. 24, Iss. 3, 2006-05 ,pp. : 203-212

Springer Publishing Company

Access to resources Recommend Favorite